A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

The immunotherapy CAN-2409 added to standard EBRT without ADT is a potential paradigm-shifting therapy for localized intermediate- to high-risk prostate cancer. CAN-2409, an adenoviral vector, plus ...

Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...